February 2026. A 47-page draft guidance drops on the FDA website. No press conference. No industry call. Just a PDF that rewrites the approval playbook for every sponsor running a pivotal program.
The new default: one adequate and well-controlled study, combined with confirmatory evidence, is sufficient for marketing authorization.
One. Not two.
That’s the end of a 28-year regulatory orthodoxy — the two-trial standard that’s dictated timelines, budgets, and career decisions since 1998. And most VPs of Clinical Development haven’t read the document.
The Three Forces That Made This Inevitable
Start with rare disease. If your target population is 200 people globally, demanding two independent pivotal studies isn’t rigorous. It’s arithmetically absurd. The agency watched programs stall for years under a standard designed for large-population indications. The February guidance on targeted individualized therapies — genome editing, antisense oligonucleotides — broke the logjam by creating a ‘plausible mechanism’ pathway. Once that door opened, the logic extended.
Then COVID. Emergency authorizations proved that single pivotal studies, designed well, generate sufficient evidence. The agency watched. The two-trial requirement didn’t improve safety signals in those programs. It would have added 18 to 24 months and $80 to $150 million to each timeline. For nothing.
Third — and this is the piece nobody’s connecting — the FDA issued its Guiding Principles of Good AI Practice in Drug Development in January 2026. Same month. Not a coincidence. The agency is building infrastructure where computational evidence, real-world data, and advanced analytics serve as confirmatory evidence alongside a single pivotal trial. They’re legislating a world where ‘evidence’ isn’t limited to randomized controlled data. The single-trial guidance is one half of that architecture.
The Confirmatory Evidence Menu — and Where Sponsors Will Get Burned
If you’re reading this as ‘great, we can skip a study,’ stop. The flexibility is real. So is the trap.
Real-world evidence from registries, claims databases, or EHR systems. The FDA is specific: pre-specified analytical plans, endpoint alignment, documented data quality. A retrospective chart review bolted on after your Phase III reads out won’t cut it. The review division will see through that in the first paragraph of the submission.
Biomarker and pharmacodynamic data. If your drug has a well-characterized mechanism and your biomarker data corroborates the clinical endpoint, that counts. Oncology and rare disease programs with response rate data supporting PFS findings — this is your path.
Earlier-phase data carried forward. Your well-designed Phase II can now serve as confirmatory evidence. Read that again. This changes how smart sponsors should be designing Phase II programs right now — not as exploratory studies, but as regulatory assets.
Strong translational and preclinical packages. For first-in-class compounds, the FDA will consider the totality of preclinical evidence. This was unthinkable five years ago.
Your Move — Before You Lock the Phase III Protocol
You’re running a biotech with a Phase II readout coming in Q3 or Q4 2026. You’re about to spend $120 million on a second pivotal trial you might not need. Here’s the decision tree.
Schedule a Type B meeting with the FDA. The agency is explicitly inviting these conversations. Do it before you finalize the Phase III protocol. Not after.
Audit your existing data. What Phase II data, biomarker packages, and RWE do you already have? Most sponsors are sitting on more confirmatory evidence than they realize. Nobody’s inventoried it because nobody thought it was relevant. Now it is.
If RWE is your confirmatory path, start your data partnership conversations today. High-quality registry data takes 6 to 9 months to access, clean, and validate. You can’t start that clock after unblinding.
The Risk That Concentrates
Single pivotal trial strategy concentrates everything into one readout. Miss it, and there’s no backup study to salvage the program.
This is where biostatistics separates the amateurs from the operators. The SAP for a single-trial program is fundamentally different. Multiplicity adjustments. Interim analysis strategy. Adaptive design elements. Sample size calculations that account for the absence of a replicate. Your Data Monitoring Committee structure needs to reflect a world where there’s no second chance.
The FDA’s message is plain: we’ll accept one trial if the evidence is compelling. The question you need to answer — honestly, before the board meeting — is whether your team can design a study that meets that standard. Or whether you’re looking for a shortcut that doesn’t exist.
